kidney cancer

Robotic nephrectomy on the rise, but why?The advantages that robotic technologies bring to prostate procedures, partial nephrectomies, and other surgeries that can involve complex reconstruction are not readily apparent in simple extirpative surgeries such as radical nephrectomy. This raises two questions: Are robots being used in radical nephrectomies and if so, why?
Robotic partial nephrectomy: Renal function loss low in CKD patientsPatients with chronic kidney disease who undergo robot-assisted partial nephrectomy for kidney cancer have minimal loss of renal function—a smaller amount even than patients with normal kidney function, according to researchers at Henry Ford Hospital in Detroit, who say their study is the largest of its kind.
Death, incidence rates of prostate cancer, other GU cancers dropBoth the death rate and incidence rate for prostate cancer continues to decline, according to the latest round of statistics from leading U.S. cancer groups.
Agent shows promise in slowing papillary kidney cancerThe first phase II study to investigate the use of the targeted therapy everolimus (Afinitor) for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease.
Study may signify shift in RCC standard of careThe tyrosine kinase inhibitors pazopanib (Votrient) and sunitinib (Sutent) had similar benefits in delaying progression of advanced renal cell carcinoma, but the safety profile and many measures of quality of life favored pazopanib, according to data from a recently published multicenter study.
Best of AUA 2013: Kidney CancerAndrew Wagner, MD, presents the take home messages on kidney cancer from the AUA annual meeting in San Diego.
Response letter received regarding new drug application for kidney cancer agentAVEO Oncology recently announced that it has received a complete response letter from the FDA informing the company that the FDA will not approve in its present form the new drug application for AVEO’s investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
Partial nephrectomy’s benefits unknown to somePhysicians and patients alike may not be aware of the benefits of nephron-sparing surgical methods, according to a recent study.
Little survival difference seen with kidney cancer agentUse of tivozanib, an experimental tyrosine kinase inhibitor (TKI) with increased specificity and potency for the vascular endothelial growth factor (VEGF) receptor, as initial targeted therapy for patients with advanced renal cell carcinoma did not translate into improved overall survival compared with sorafenib (Nexavar) in a phase 3 clinical trial.
Kidney Ca data could help individualize treatmentResearchers at UCLA’s Institute of Urologic Oncology and department of urology have classified kidney cancer into several unique subtypes, a finding that could help physicians tailor treatment to individual patients.